These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 26416653)

  • 1. Determinant Factors of the Direct Medical Costs Associated with Genotype 1 Hepatitis C Infection in Treatment-Experienced Patients.
    Akpo EI; Sbarigia U; Wan G; Kleintjens J
    Drugs R D; 2015 Dec; 15(4):335-49. PubMed ID: 26416653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.
    Saab S; Gordon SC; Park H; Sulkowski M; Ahmed A; Younossi Z
    Aliment Pharmacol Ther; 2014 Sep; 40(6):657-75. PubMed ID: 25065960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting the impact of adverse events and treatment duration on medical resource utilization-related costs in hepatitis C genotype 1 treatment-naïve patients receiving antiviral therapy.
    Akpo EI; Cerri K; Kleintjens J
    Pharmacoeconomics; 2015 Apr; 33(4):409-22. PubMed ID: 25577042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cost utility analysis of simeprevir used with peginterferon + ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health Service.
    Westerhout K; Treur M; Mehnert A; Pascoe K; Ladha I; Belsey J
    J Med Econ; 2015; 18(10):838-49. PubMed ID: 25903830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients.
    Cure S; Bianic F; Gavart S; Curtis S; Lee S; Dusheiko G
    J Med Econ; 2014 Jan; 17(1):77-87. PubMed ID: 24032626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients.
    Cure S; Bianic F; Gavart S; Curtis S; Lee S; Dusheiko G
    J Med Econ; 2014 Jan; 17(1):65-76. PubMed ID: 24160335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy of chronic hepatitis C with PEG-IFN α-2b plus ribavirin in patients with genotype 2 or 3: 16 versus 24 weeks, clinical outcome and direct cost analyses.
    Fabris P; Carlotto A; Del Bianco T; Malfatti F; Tramarin A; Miotti MA; Baldo V; Floreani A; Giordani MT; Grasso A
    Eur J Gastroenterol Hepatol; 2013 Dec; 25(12):1396-401. PubMed ID: 23743559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of groups with poor cost-effectiveness of peginterferon plus ribavirin for naïve hepatitis C patients with a real-world cohort and database.
    Tsai PC; Liu TW; Tsai YS; Ko YM; Chen KY; Lin CC; Huang CI; Liang PC; Lin YH; Hsieh MY; Hou NJ; Huang CF; Yeh ML; Lin ZY; Chen SC; Dai CY; Chuang WL; Huang JF; Yu ML
    Medicine (Baltimore); 2017 Jun; 96(22):e6984. PubMed ID: 28562549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A real-world impact of cost-effectiveness of pegylated interferon/ribavarin regimens on treatment-naïve chronic hepatitis C patients in Taiwan.
    Tsai PC; Liu TW; Hsieh MH; Yeh ML; Liang PC; Lin YH; Huang CI; Huang CF; Hsieh MY; Hou NJ; Lin ZY; Chen SC; Huang JF; Dai CY; Chuang WL; Yu ML
    Kaohsiung J Med Sci; 2017 Jan; 33(1):44-49. PubMed ID: 28088273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis.
    Athanasakis K; Ferrante SA; Kyriopoulos II; Petrakis I; Hill M; Retsa MP; Kyriopoulos J
    Clin Ther; 2015 Jul; 37(7):1529-40. PubMed ID: 26031617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Financial impact of two different ways of evaluating early virological response to peginterferon-alpha-2b plus ribavirin therapy in treatment-naive patients with chronic hepatitis C virus genotype 1.
    Buti M; Casado MA; Fosbrook L; Esteban R
    Pharmacoeconomics; 2005; 23(10):1043-55. PubMed ID: 16235977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain.
    Turnes J; Romero-Gómez M; Planas R; Solà R; García-Samaniego J; Diago M; Crespo J; Calleja JL; Rubio-Terrés C; Ventayol P
    Gastroenterol Hepatol; 2013 Nov; 36(9):555-64. PubMed ID: 24119723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimation of direct medical cost related to the management of chronic hepatitis C and its complications in South Korea.
    Kim DY; Yoon KT; Kim W; Lee JI; Hong SH; Lee D; Jang JW; Choi JW; Kim I; Paik YH
    Medicine (Baltimore); 2016 Jul; 95(30):e3896. PubMed ID: 27472670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of boceprevir co-administration versus pegylated interferon-α2b and ribavirin only for patients with hepatitis C genotype 1 in Singapore.
    Dan YY; Ferrante SA; Elbasha EH; Hsu TY
    Antivir Ther; 2015; 20(2):209-16. PubMed ID: 25105844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.
    Sullivan SD; Craxi A; Alberti A; Giuliani G; De Carli C; Wintfeld N; Patel KK; Green J
    Pharmacoeconomics; 2004; 22(4):257-65. PubMed ID: 14974875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial.
    Reddy KR; Zeuzem S; Zoulim F; Weiland O; Horban A; Stanciu C; Villamil FG; Andreone P; George J; Dammers E; Fu M; Kurland D; Lenz O; Ouwerkerk-Mahadevan S; Verbinnen T; Scott J; Jessner W
    Lancet Infect Dis; 2015 Jan; 15(1):27-35. PubMed ID: 25482330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C.
    Carrión JA; Gonzalez-Colominas E; García-Retortillo M; Cañete N; Cirera I; Coll S; Giménez MD; Márquez C; Martin-Escudero V; Castellví P; Navinés R; Castaño JR; Galeras JA; Salas E; Bory F; Martín-Santos R; Solà R
    J Hepatol; 2013 Nov; 59(5):926-33. PubMed ID: 23811030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost utility of telaprevir-PR (peginterferon-ribavirin) versus boceprevir-PR and versus PR alone in chronic hepatitis C in The Netherlands.
    Vellopoulou A; van Agthoven M; van der Kolk A; de Knegt RJ; Berdeaux G; Cure S; Bianic F; Lamotte M
    Appl Health Econ Health Policy; 2014 Dec; 12(6):647-59. PubMed ID: 25103219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cost-effectiveness analysis of sofosbuvir, peginterferon and ribavirin in patients with chronic hepatitis C: Early treatment in the initial stage of fibrosis vs. delayed treatment in advanced fibrosis].
    Buti M; Domínguez-Hernández R; Oyagüez I; Casado MÁ
    Gastroenterol Hepatol; 2016; 39(7):449-57. PubMed ID: 27084669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct medical care costs among pegylated interferon plus ribavirin-treated and untreated chronic hepatitis C patients.
    Solomon M; Bonafede M; Pan K; Wilson K; Beam C; Chakravarti P; Spiegel B
    Dig Dis Sci; 2011 Oct; 56(10):3024-31. PubMed ID: 21717127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.